CARISMA THERAPEUTICS INC (CARM)
US14216R1014 - Common Stock
These stocks have an unusual volume in today's session
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
What's going on in today's session
The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session.
Friday's session: gap up and gap down stocks
What's going on in today's pre-market session
Top movers in Friday's pre-market session
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower!
These stocks are moving in today's after hours session
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
CARM Stock Earnings: CARISMA Therapeutics Misses EPS, Misses Revenue for Q1 2024
CARM stock results show that CARISMA Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
CARM Stock Earnings: CARISMA Therapeutics Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CARISMA Therapeutics (NASDAQ:CARM) just reported results for the first quarter ...
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q4 2023
CARM stock results show that CARISMA Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
FDA clears IND application for Carisma cellular therapy (NASDAQ:CARM)
Carisma Therapeutics gains 14% premarket as FDA approves IND application for novel cellular therapy to treat solid tumors overexpressing HER2.
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
3 Top Under-$5 Stocks for Strong Gains and Positive Outlook
If you can handle the stomach-churning volatility and know when to call it quits, these top stocks under $5 could be intriguing.
Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma Therapeutics" or the "Company"), a clinical stage biopharmaceutical company focused on...
Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday!
Carisma Therapeutics to Present at the JMP Securities Life Sciences Conference
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma"), a clinical stage biopharmaceutical company focused on discovering and developing...